Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1073699

Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant Effect of Apixaban in Adolescents?


Ćelap, Ivana; Margetić, Sandra; Mihić, Roman; Obuljen, Jasna; Linarić, Irena; Leniček Krleža, Jasna
Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant Effect of Apixaban in Adolescents? // Res Pract Thromb Haemost / Cushman, Mary (ur.).
Medford: Wiley, 2020. PB2355, 1 (poster, međunarodna recenzija, sažetak, znanstveni)


CROSBI ID: 1073699 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant Effect of Apixaban in Adolescents?

Autori
Ćelap, Ivana ; Margetić, Sandra ; Mihić, Roman ; Obuljen, Jasna ; Linarić, Irena ; Leniček Krleža, Jasna

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Res Pract Thromb Haemost / Cushman, Mary - Medford : Wiley, 2020

Skup
ISTH 2020

Mjesto i datum
Virtual Congress, 12.-14.07.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
anti Xa assay, apixaban, adolescents
(antiepileptics, platelet aggregation)

Sažetak
Background: Although clinical application of apixaban does not require coagulation monitoring, there are clinical situations in which measurement of drug concentration should be performed. Anti-activated factor Xa (anti- FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin-calibrated anti-FXa assay as an alternative method for direct FXa inhibitors. Aims: To assess whether commercial low molecular weight heparin (LMWH)-calibrated anti-FXa assay can be used for assessing anticoagulant effect of apixaban in adolescents. Methods: LMWH-calibrated anti-FXa method (Innovance heparin, Siemens Healthineers, Germany) was used for measurement of LMWH anti- FXa activity. Innovance heparin (Siemens Healthineers, Germany) calibrated with apixaban calibrators (Hyphen BioMed, France) was used for quantitative determination of apixaban concentration. Agreement between LMWH and apixaban calibrated anti-FXa assays was tested using kappa statistics whereas receiver operating characteristics (ROC) analysis was performed for LMWH therapeutic range. The study was funded by the Croatian Science Foundation as part of the research project IP-2016-06- 8208. Results: In 36 plasma samples of 11 adolescents (13-22 years), concentrations of apixaban ranged from 20 ng/mL to 267 ng/mL (median 94 ng/mL). LMWH anti-FXa activity ranged from 0.11 to 1.50 (upper LMWH measuring range) (median 0.68 IU/mL) (Table 1). Inter-rater aggrement analysis showed poor agreement (κ=0.16 ; 95%CI – 0.0327 to 0.3386) between therapeutic range of LMWH-calibrated anti-FXa activity and clinically relevant apixaban concentrations (>30 ng/mL) (Table 2). ROC analysis showed that only apixaban concentrations between 57 and 121 ng/mL could be expected with certainty within therapeutic range for LMWH anti-FXa activity. Cut-off value for LMWH anti-FXa activity for apixaban concentrations < 30 ng/mL is 0.12 IU/mL. Conclusions: LMWH anti-FXa activity assay is not appropriate method for quantitative estimation of apixaban concentration and should not be used as an interchangeable method. Quantitative measurement of apixaban concentration should be performed in all clinical situations.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekti:
HRZZ-IP-2016-06-8208 - Novi oralni antikoagulansi: povezanost koncentracije lijeka i antikoagulantnog učinka (LAB-NOAC) (Margetić, Sandra, HRZZ - 2016-06) ( POIROT)

Ustanove:
KBC "Sestre Milosrdnice",
Klinika za dječje bolesti

Citiraj ovu publikaciju

Ćelap, Ivana; Margetić, Sandra; Mihić, Roman; Obuljen, Jasna; Linarić, Irena; Leniček Krleža, Jasna
Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant Effect of Apixaban in Adolescents? // Res Pract Thromb Haemost / Cushman, Mary (ur.).
Medford: Wiley, 2020. PB2355, 1 (poster, međunarodna recenzija, sažetak, znanstveni)
Ćelap, I., Margetić, S., Mihić, R., Obuljen, J., Linarić, I. & Leniček Krleža, J. (2020) Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant Effect of Apixaban in Adolescents?. U: Cushman, M. (ur.)Res Pract Thromb Haemost.
@article{article, editor = {Cushman, M.}, year = {2020}, pages = {1}, chapter = {PB2355}, keywords = {anti Xa assay, apixaban, adolescents}, title = {Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant Effect of Apixaban in Adolescents?}, keyword = {anti Xa assay, apixaban, adolescents}, publisher = {Wiley}, publisherplace = {Virtual Congress}, chapternumber = {PB2355} }
@article{article, editor = {Cushman, M.}, year = {2020}, pages = {1}, chapter = {PB2355}, keywords = {antiepileptics, platelet aggregation}, title = {Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant Effect of Apixaban in Adolescents?}, keyword = {antiepileptics, platelet aggregation}, publisher = {Wiley}, publisherplace = {Virtual Congress}, chapternumber = {PB2355} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Emerging Sources Citation Index (ESCI)





Contrast
Increase Font
Decrease Font
Dyslexic Font